Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug discovery process. The company, founded in 2013, has been working on that project ...
SALT LAKE CITY - Recursion (NASDAQ:RXRX) announced Monday that Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026, replacing David Mauro, M.D., Ph.D., who is transitioning ...
Artificial intelligence (AI) has the potential to transform all sectors and industries throughout the economy. Investing in companies that are involved in this transformation can potentially result in ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results